Regulation of recombination in Mycoplasma genitalium

生殖支原体重组的调控

基本信息

  • 批准号:
    9371810
  • 负责人:
  • 金额:
    $ 23.24万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-06-01 至 2019-05-31
  • 项目状态:
    已结题

项目摘要

ABSTRACT Mycoplasma genitalium (MG) is a sexually transmitted pathogen, recognized as an important cause of several reproductive tract disease syndromes in men and women. Despite the inflammation and specific antibodies produced by the host, MG infections are often chronic, persisting for many months if not treated with effective antibiotic therapy. We and others have shown that the adhesins of MG, MgpB and MgpC, undergo phase and antigenic variation, likely contributing to evasion of the host immune response, persistence, and reinfection. MgpBC variation is mediated by a unique system of segmental reciprocal recombination between the mgpBC expression site and archived homologous partial copies of these genes, termed MgPars, located throughout the MG chromosome. However, the components required for mgpBC/MgPar recombination and their regulation are incompletely understood, in part due to the difficulty of working with this fastidious bacterium and the absence of a complete set of recombination genes and regulators in MG's tiny genome (580 kb). The goal of this proposal is to characterize the regulatory mechanism(s) mediating mgpBC/MgPar recombination, and therefore antigenic variation, in MG. Recently, we discovered that MG428 positively regulates recombination enzymes (recA, ruvA, and ruvB) and determined that this protein is a previously uncharacterized, extracytoplasmic function (ECF) sigma factor. We have also shown that, unique to MG, RecA is expressed as three distinct isoforms generated by alternative translation initiation: an active, full-length RecA and two inactive, N-terminally truncated versions of this protein. We propose that the small isoforms regulate mgpBC/MgPar recombination in MG by inhibiting the activity of full-length RecA. Further, we have determined that a novel protein of unknown function reduces antigenic and phase variation. We hypothesize that this putative membrane protein controls mgpBC/MgPar recombination in response to environmental signals. In addition, we have determined that growth in low CO2 enhances antigenic and phase variation rates. Building on these preliminary findings, we seek funding to explore the function of the truncated isoforms on full-length RecA activity (Aim 1), define the mechanism by which antigenic and phase variation is reduced by our newly identified membrane protein, including its putative network of interacting partners (Aim 2), and explore how CO2 and other environmental conditions affect this process (Aim 3). Finally we will investigate the effect of these conditions on recombination gene transcription and the expression of RecA isoforms, thereby defining the pathways controlling mgpBC/MgPar recombination in this organism. We anticipate that this study will reveal a novel, complex, and tightly regulated system of antigenic and phase variation mediating survival and evasion of the host immune response in a clinically significant and extremely fastidious pathogen.
摘要

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

PATRICIA A TOTTEN其他文献

PATRICIA A TOTTEN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('PATRICIA A TOTTEN', 18)}}的其他基金

Phase Variation in Mycoplasma Genitalium
生殖支原体的相变
  • 批准号:
    8770935
  • 财政年份:
    2014
  • 资助金额:
    $ 23.24万
  • 项目类别:
Phase Variation in Mycoplasma Genitalium
生殖支原体的相变
  • 批准号:
    8849837
  • 财政年份:
    2014
  • 资助金额:
    $ 23.24万
  • 项目类别:
Mycoplasma genitalium variation in longitudinally infected men
纵向感染男性的生殖支原体变异
  • 批准号:
    8569706
  • 财政年份:
    2013
  • 资助金额:
    $ 23.24万
  • 项目类别:
Mycoplasma genitalium variation in longitudinally infected men
纵向感染男性的生殖支原体变异
  • 批准号:
    8721850
  • 财政年份:
    2013
  • 资助金额:
    $ 23.24万
  • 项目类别:
Recombination in a Minimal Organism
最小生物体内的重组
  • 批准号:
    8385992
  • 财政年份:
    2012
  • 资助金额:
    $ 23.24万
  • 项目类别:
Recombination in a Minimal Organism
最小生物体内的重组
  • 批准号:
    8515926
  • 财政年份:
    2012
  • 资助金额:
    $ 23.24万
  • 项目类别:
SALPINGEAL INFECTION NODAL OF MYCOPLASMA GENITALIUM
生殖支原体输卵管感染淋巴结
  • 批准号:
    8357618
  • 财政年份:
    2011
  • 资助金额:
    $ 23.24万
  • 项目类别:
PRIMATE MODEL FOR MYCOPLASMA GENITALIUM
生殖支原体灵长类动物模型
  • 批准号:
    8357617
  • 财政年份:
    2011
  • 资助金额:
    $ 23.24万
  • 项目类别:
SALPINGEAL INFECTION NODAL OF MYCOPLASMA GENITALIUM
生殖支原体输卵管感染淋巴结
  • 批准号:
    8172791
  • 财政年份:
    2010
  • 资助金额:
    $ 23.24万
  • 项目类别:
PRIMATE MODEL FOR MYCOPLASMA GENITALIUM
生殖支原体灵长类动物模型
  • 批准号:
    8172790
  • 财政年份:
    2010
  • 资助金额:
    $ 23.24万
  • 项目类别:

相似海外基金

SBIR Phase II: Development of a urine dipstick test that can guide immediate and appropriate antibiotic therapy for treatment of complicated urinary tract infections
SBIR II 期:开发尿液试纸测试,可以指导复杂尿路感染的立即和适当的抗生素治疗
  • 批准号:
    2213034
  • 财政年份:
    2023
  • 资助金额:
    $ 23.24万
  • 项目类别:
    Cooperative Agreement
Personalized Antibiotic Therapy in the Emergency Department: PANTHER Trial
急诊科的个性化抗生素治疗:PANTHER 试验
  • 批准号:
    10645528
  • 财政年份:
    2023
  • 资助金额:
    $ 23.24万
  • 项目类别:
Strategies for improving the efficacy of combinatorial antibiotic therapy in chronic infections
提高慢性感染联合抗生素治疗疗效的策略
  • 批准号:
    10736285
  • 财政年份:
    2023
  • 资助金额:
    $ 23.24万
  • 项目类别:
A Novel Bone Targeted Antibiotic Therapy for the Treatment of Infected Fractures
一种治疗感染性骨折的新型骨靶向抗生素疗法
  • 批准号:
    10603486
  • 财政年份:
    2023
  • 资助金额:
    $ 23.24万
  • 项目类别:
Severe Cutaneous Adverse Reactions Following Outpatient Antibiotic Therapy: A Population-based Study
门诊抗生素治疗后的严重皮肤不良反应:一项基于人群的研究
  • 批准号:
    449379
  • 财政年份:
    2020
  • 资助金额:
    $ 23.24万
  • 项目类别:
    Studentship Programs
Sex-Specific Differences in End-of-Life Burdensome Interventions and Antibiotic Therapy in Nursing Home Residents With Advanced Dementia
患有晚期痴呆症的疗养院居民的临终干预和抗生素治疗的性别差异
  • 批准号:
    422034
  • 财政年份:
    2020
  • 资助金额:
    $ 23.24万
  • 项目类别:
Optimizing outpatient parenteral antibiotic therapy to support hospital-in-the-home program across the unique environmental conditions of Australia
优化门诊肠外抗生素治疗,以支持澳大利亚独特环境条件下的家庭医院计划
  • 批准号:
    nhmrc : 1197866
  • 财政年份:
    2020
  • 资助金额:
    $ 23.24万
  • 项目类别:
    Investigator Grants
Resistance evolution in the presence of combination antibiotic therapy
联合抗生素治疗下耐药性的演变
  • 批准号:
    2241853
  • 财政年份:
    2019
  • 资助金额:
    $ 23.24万
  • 项目类别:
    Studentship
Host-pathogen interactions in antibiotic therapy for listeriosis
李斯特菌病抗生素治疗中宿主与病原体的相互作用
  • 批准号:
    18K07106
  • 财政年份:
    2018
  • 资助金额:
    $ 23.24万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Multipurpose targeted nano-antibiotic therapy to fight tough infection in bones
多用途靶向纳米抗生素疗法可对抗骨骼中的严重感染
  • 批准号:
    9788269
  • 财政年份:
    2018
  • 资助金额:
    $ 23.24万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了